Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
- Hertz cuts guidance, announces notes and stock offerings, shares sink
Seres Therapeutics (MCRB) Reports In-Line Q1 EPS, Revenues Miss
May 7, 2020 7:57 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.28), in-line with the analyst estimate of ($0.28). Revenue for the quarter came in at $8.19 million versus the consensus estimate of $8.53 million.
We were pleased to have recently achieved the important milestone of completing enrollment of our... More
